Baaboon的个人主页 - 老虎社区

Baaboon

暂无个人介绍

IP属地：未知

2关注

0粉丝

0主题

0勋章

2021-12-08

Meme your mother

Meme stocks jumped in morning trading

2021-12-07

I am betting on your mother

Ocugen Investors Are Betting On a Horse Than Can’t Win the Race

2021-10-21

Mother fool

7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen

2021-04-23

Retarded face

Singapore names new finance minister in cabinet reshuffle after setback in leadership succession

2021-04-21

Please talk about Ocugen OCGN. They will be saving the world, together with India.

Toplines Before US Market Open on Wednesday

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577579226988656","uuid":"3577579226988656","gmtCreate":1614485203854,"gmtModify":1614485203854,"name":"Baaboon","pinyin":"baaboon","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.77%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":602333381,"gmtCreate":1638969966940,"gmtModify":1638969966940,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Meme your mother&nbsp;","listText":"Meme your mother&nbsp;","text":"Meme your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602333381","repostId":"1160989369","repostType":2,"repost":{"id":"1160989369","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890853,"share":"https://www.laohu8.com/m/news/1160989369?lang=&edition=full","pubTime":"2021-12-07 23:27","market":"us","language":"en","title":"Meme stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1160989369","media":"Tiger Newspress","summary":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisit","content":"<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p>\n<p><img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 23:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p>\n<p><img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","ZOM":"Zomedica Pharmaceuticals Corp.","BBIG":"Vinco Ventures, Inc.","ATER":"Aterian Inc.","KOSS":"高斯电子","EXPR":"Express, Inc.","GME":"游戏驿站","MRIN":"Marin Software Inc.","NEGG":"Newegg Comm Inc.","CLOV":"Clover Health Corp","GREE":"Greenidge Generation Holdings Inc.","OCGN":"Ocugen","BB":"黑莓","PHUN":"Phunware, Inc.","BBBY":"3B家居"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160989369","content_text":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC and GameStop climbed between 5% and 18%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1009,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606614244,"gmtCreate":1638870615594,"gmtModify":1638870615594,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"I am betting on&nbsp;your mother","listText":"I am betting on&nbsp;your mother","text":"I am betting on your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606614244","repostId":"1159607563","repostType":2,"repost":{"id":"1159607563","kind":"news","pubTimestamp":1638861435,"share":"https://www.laohu8.com/m/news/1159607563?lang=&edition=full","pubTime":"2021-12-07 15:17","market":"us","language":"en","title":"Ocugen Investors Are Betting On a Horse Than Can’t Win the Race","url":"https://stock-news.laohu8.com/highlight/detail?id=1159607563","media":"InvestorPlace","summary":"Don't go bottom-fishing with OCGN stock even if it's at an enticing support level","content":"<p>For technical traders, it might be tempting to accumulate shares of biopharmaceutical company&nbsp;<b>Ocugen</b>&nbsp;(NASDAQ:<b><u>OCGN</u></b>) because OCGN stock has come down to a seemingly fair price.</p>\n<p>Yet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.</p>\n<p>So, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.</p>\n<p>Moreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.</p>\n<p><b>A Closer Look at OCGN Stock</b></p>\n<p>Before talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.</p>\n<p>In February, May and November, the stock spiked to $15 before declining sharply.</p>\n<p>Therefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.</p>\n<p>On the other end of the spectrum, OCGN stock has strong support at $6.</p>\n<p>The stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.</p>\n<p>Checking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.</p>\n<p>Therefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.</p>\n<p>So, let’s see how Ocugen’s faring on the fiscal front.</p>\n<p><b>Financially Frail</b></p>\n<p>Just to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is&nbsp;known as Covaxin.</p>\n<p>Ocugen is&nbsp;co-developing&nbsp;Covaxin with India-based&nbsp;<b>Bharat Biotech</b>, and is advancing the drug in the U.S. and Canadian markets.</p>\n<p>It’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.</p>\n<p>Let’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.</p>\n<p>Right now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.</p>\n<p>During&nbsp;2021’s third quarter, Ocugen generated zero total revenues.</p>\n<p>The same could actually be said about the first three quarters of 2021.</p>\n<p>Now, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.</p>\n<p>That’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.</p>\n<p>So far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?</p>\n<p><b>Good News, Bad News</b></p>\n<p>Let’s start with a development that should provide some relief to OCGN stock holders.</p>\n<p><i>The Lancet</i>, a widely respected medical journal,published the results&nbsp;of a Phase 3 trial of Covaxin.</p>\n<p>The data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.</p>\n<p>That’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.</p>\n<p>Those lower figures might make Covaxin less useful in certain contexts.</p>\n<p>Worse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.</p>\n<p>That’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.</p>\n<p>The competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.</p>\n<p>Therefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Investors Are Betting On a Horse Than Can’t Win the Race</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Investors Are Betting On a Horse Than Can’t Win the Race\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the...</p>\n\n<a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159607563","content_text":"For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.\nSo, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.\nMoreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.\nA Closer Look at OCGN Stock\nBefore talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.\nIn February, May and November, the stock spiked to $15 before declining sharply.\nTherefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.\nOn the other end of the spectrum, OCGN stock has strong support at $6.\nThe stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.\nChecking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.\nTherefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.\nSo, let’s see how Ocugen’s faring on the fiscal front.\nFinancially Frail\nJust to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is known as Covaxin.\nOcugen is co-developing Covaxin with India-based Bharat Biotech, and is advancing the drug in the U.S. and Canadian markets.\nIt’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.\nLet’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.\nRight now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.\nDuring 2021’s third quarter, Ocugen generated zero total revenues.\nThe same could actually be said about the first three quarters of 2021.\nNow, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.\nThat’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.\nSo far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?\nGood News, Bad News\nLet’s start with a development that should provide some relief to OCGN stock holders.\nThe Lancet, a widely respected medical journal,published the results of a Phase 3 trial of Covaxin.\nThe data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.\nThat’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.\nThose lower figures might make Covaxin less useful in certain contexts.\nWorse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.\nThat’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.\nThe Bottom Line\nIt’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.\nThe competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.\nTherefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1029,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853539585,"gmtCreate":1634823296736,"gmtModify":1634823712607,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Mother fool","listText":"Mother fool","text":"Mother fool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853539585","repostId":"1171915283","repostType":2,"repost":{"id":"1171915283","kind":"news","pubTimestamp":1634817585,"share":"https://www.laohu8.com/m/news/1171915283?lang=&edition=full","pubTime":"2021-10-21 19:59","market":"us","language":"en","title":"7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen","url":"https://stock-news.laohu8.com/highlight/detail?id=1171915283","media":"Motley Fool","summary":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so f","content":"<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p>\n<p>Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p>\n<p>1. A path to EUA in the U.S.</p>\n<p>Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p>\n<p>The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p>\n<p>Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p>\n<p>Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p>\n<p>2. Supply deals already in hand</p>\n<p>Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p>\n<p>Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p>\n<p>3. Full rights to its COVID-19 vaccine</p>\n<p>Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p>\n<p>Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p>\n<p>4. A stronger pipeline</p>\n<p>Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p>\n<p>Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p>\n<p>5. More cash</p>\n<p>Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p>\n<p>As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p>\n<p>6. More potential near-term catalysts</p>\n<p>Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p>\n<p>What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p>\n<p>7. A more defensible valuation</p>\n<p>Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p>\n<p>Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171915283","content_text":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes that make Ocugen the smarter vaccine stock to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.\n1. A path to EUA in the U.S.\nOcugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.\nThe company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.\nMeanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.\nOcugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.\n2. Supply deals already in hand\nSome investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.\nOcugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,Takeda), and Gavi, the Vaccine Alliance.\n3. Full rights to its COVID-19 vaccine\nOcugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.\nNovavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.\n4. A stronger pipeline\nOther than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.\nNovavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.\n5. More cash\nCash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.\nAs of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.\n6. More potential near-term catalysts\nOcugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.\nWhat about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.\n7. A more defensible valuation\nOcugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.\nNovavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.","news_type":1},"isVote":1,"tweetType":1,"viewCount":851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":372941567,"gmtCreate":1619171841559,"gmtModify":1634288015707,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Retarded&nbsp;face","listText":"Retarded&nbsp;face","text":"Retarded face","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/372941567","repostId":"1144940040","repostType":4,"repost":{"id":"1144940040","kind":"news","pubTimestamp":1619165890,"share":"https://www.laohu8.com/m/news/1144940040?lang=&edition=full","pubTime":"2021-04-23 16:18","market":"sg","language":"en","title":"Singapore names new finance minister in cabinet reshuffle after setback in leadership succession","url":"https://stock-news.laohu8.com/highlight/detail?id=1144940040","media":"cnbc","summary":"KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new fi","content":"<div>\n<p>KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new finance minister.Wong is the current education minister and second finance minister, and has been ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore names new finance minister in cabinet reshuffle after setback in leadership succession</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore names new finance minister in cabinet reshuffle after setback in leadership succession\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 16:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new finance minister.Wong is the current education minister and second finance minister, and has been ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1144940040","content_text":"KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new finance minister.Wong is the current education minister and second finance minister, and has been tipped as one of the potential successors to Lee.Wong will take over from Heng Swee Keat, who announced two weeks ago that he will step aside as Lee’s designated successor.SINGAPORE — Singapore’s Prime Minister Lee Hsien Loong has named a new finance minister, replacing Heng Swee Keat who announced two weeks ago that he willstep aside as Lee’s designated successor.Lawrence Wong, the country’s current education minister and second finance minister, will helm the finance portfolio from May 15,the prime minister’s office said on Friday.Wong is also the co-chair of Singapore’s taskforce on Covid-19, and has risen in prominence since the coronavirus outbreak last year.Wong is among potential candidatesthat analysts said could eventually take over from Lee as prime minister.The cabinet shuffle came after Heng's announcement threw Singapore's carefully planned leadership succession into disarray. Heng, who's 60 this year, had cited his age as an obstacle in steering the country in a post-pandemic world.Heng will relinquish his role as finance minister, but remains the country's deputy prime minister and coordinating minister for economic policies.In addition to Wong, analysts identified three other potential candidates for prime minister:Minister for Trade and Industry Chan Chun Sing, 51, who will become education minister in the new cabinet.Minister for Transport Ong Ye Kung, 51, who will become health minister.Desmond Lee, 44, who will remain as minister for national development.The ruling People’s Action Party has governed Singapore since the country’s independence in 1965. The party suffered one of itsworst electoral showingslast year, winning 83 out of 93 parliamentary seats and 61% of the votes.Lee, the current prime minister, had previously said he was ready to retireby the time he turns 70. However, he later indicated he would delay his handover to see Singapore through the Covid-19 crisis.Lee is 69 this year.After Heng’s surprise announcement, Lee said he would stay on as prime minister until a new successor emerges and is ready to take over.","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378192346,"gmtCreate":1619008614285,"gmtModify":1634289268600,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","listText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","text":"Please talk about Ocugen OCGN. They will be saving the world, together with India.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/378192346","repostId":"1133987686","repostType":4,"repost":{"id":"1133987686","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619007348,"share":"https://www.laohu8.com/m/news/1133987686?lang=&edition=full","pubTime":"2021-04-21 20:15","market":"us","language":"en","title":"Toplines Before US Market Open on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1133987686","media":"Tiger Newspress","summary":"Netflix drags down nasdaq futuresTreasuries halt rally after 10-year yield slid to 5-week lowU.S. fu","content":"<ul><li>Netflix drags down nasdaq futures</li></ul><ul><li>Treasuries halt rally after 10-year yield slid to 5-week low</li></ul><p>U.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.</p><p>At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&amp;P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c293a0649fd6c7c229a3ec2b0b714acf\" tg-width=\"1080\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:00</span></p><p>Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.</p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><b>Netflix&nbsp;(NFLX) </b>– Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.</p><p><b>ASML&nbsp;(ASML)</b> – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.</p><p><b>Moderna&nbsp;(MRNA)</b> – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.</p><p><b>Norwegian Cruise Line&nbsp;(NCLH)</b> – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.</p><p><b>Verizon&nbsp;(VZ) </b>– Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.</p><p><b>Welbilt&nbsp;(WBT)</b> – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival&nbsp;Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.</p><p><b>Anthem&nbsp;(ANTM) </b>– The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.</p><p><b>Nasdaq&nbsp;(NDAQ)</b> – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.</p><p><b>Halliburton&nbsp;(HAL)</b> – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.</p><p><b>Baker Hughes&nbsp;(BKR)</b> – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.</p><p><b>CSX&nbsp;(CSX) </b>– CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.</p><p><b>Intuitive Surgical&nbsp;(ISRG)</b> – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.</p><p><b>Tenet Healthcare&nbsp;(THC) </b>– Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.</p><p><b>Interactive Brokers&nbsp;(IBKR)</b> – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.</p><p><b>Edwards Lifesciences&nbsp;(EW) </b>– Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-21 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul><li>Netflix drags down nasdaq futures</li></ul><ul><li>Treasuries halt rally after 10-year yield slid to 5-week low</li></ul><p>U.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.</p><p>At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&amp;P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c293a0649fd6c7c229a3ec2b0b714acf\" tg-width=\"1080\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:00</span></p><p>Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.</p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><b>Netflix&nbsp;(NFLX) </b>– Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.</p><p><b>ASML&nbsp;(ASML)</b> – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.</p><p><b>Moderna&nbsp;(MRNA)</b> – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.</p><p><b>Norwegian Cruise Line&nbsp;(NCLH)</b> – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.</p><p><b>Verizon&nbsp;(VZ) </b>– Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.</p><p><b>Welbilt&nbsp;(WBT)</b> – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival&nbsp;Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.</p><p><b>Anthem&nbsp;(ANTM) </b>– The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.</p><p><b>Nasdaq&nbsp;(NDAQ)</b> – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.</p><p><b>Halliburton&nbsp;(HAL)</b> – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.</p><p><b>Baker Hughes&nbsp;(BKR)</b> – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.</p><p><b>CSX&nbsp;(CSX) </b>– CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.</p><p><b>Intuitive Surgical&nbsp;(ISRG)</b> – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.</p><p><b>Tenet Healthcare&nbsp;(THC) </b>– Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.</p><p><b>Interactive Brokers&nbsp;(IBKR)</b> – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.</p><p><b>Edwards Lifesciences&nbsp;(EW) </b>– Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WBT":" Manitowoc Food Service","HAL":"哈里伯顿","NFLX":"奈飞","NCLH":"挪威邮轮","MRNA":"Moderna, Inc.","THC":"泰尼特",".DJI":"道琼斯","NDAQ":"纳斯达克OMX交易所",".IXIC":"NASDAQ Composite","VZ":"威瑞森",".SPX":"S&P 500 Index","ASML":"阿斯麦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133987686","content_text":"Netflix drags down nasdaq futuresTreasuries halt rally after 10-year yield slid to 5-week lowU.S. futures were mixed as underperformance in the Nasdaq 100 signaled the rotation away from pandemic favorites is gaining ground. Treasury yields halted a slide that had taken them to a five-week low.At 8:00 a.m. ET, Dow e-minis were up 11 points, or 0.03%, S&P 500 e-minis were down 0.75 points, or 0.02%, and Nasdaq 100 e-minis were down 26.75 points, or 0.19%.*Source From Tiger Trade, EST 08:00Netflix,the streaming service provider tumbled 8.5% in premarket trading after its report showed slower production of TV shows and movies during the pandemic hurt subscriber growth in the first quarter.Stocks making the biggest moves in the premarket:Netflix (NFLX) – Netflix tumbled 8.5% in premarket trading, even after beating estimates on both the top and bottom lines for its latest quarter. Investors are focusing on weaker-than-expected subscriber growth numbers for the video streaming giant.ASML (ASML) – ASML gained 3.9% in premarket action after it reported better-than-expected first-quarter profit, as the supplier of semiconductor manufacturing equipment benefits from the global surge in chip demand. ASML also raised its full-year outlook.Moderna (MRNA) – The drugmaker’s shares gained 0.5% in premarket trading, after it struck a new Covid-19 vaccine supply deal with Israel for 2022. Israel also got an option to buy doses of vaccine designed to treat specific variants of the virus.Norwegian Cruise Line (NCLH) – Norwegian shares rose 1.8% in the premarket after Goldman Sachs upgraded the cruise line operator to “buy” from “neutral.” Goldman cited several positive factors including Norwegian’s capacity growth and low leverage compared to its peers.Verizon (VZ) – Verizon reported quarterly earnings of $1.31 per share, 2 cents a share above estimates. Revenue also beat analysts' forecasts. Verizon lost more wireless subscribers during the quarter than analysts had been anticipating.Welbilt (WBT) – Welbilt shares surged 20% in the premarket after the maker of professional foodservice equipment agreed to be bought by rival Middleby(MIDD) in an all-stock transaction with an implied value of $4.3 billion.Anthem (ANTM) – The health insurer earned $7.01 per share for its latest quarter, beating estimates by 50 cents a share. Revenue fell short of Wall Street projections. Anthem also raised its full-year outlook, amid growth in its various medical plans and higher pharmacy benefit management revenue. The stock rose 1.6% in premarket trading.Nasdaq (NDAQ) – The stock exchange operator earned $1.96 per share for the first quarter, 23 cents a share above estimates. Revenue also came in above Street forecasts. Results were boosted by double-digit increases in equity and fixed income trading revenue. Nasdaq also announced a 10% dividend increase.Halliburton (HAL) – Halliburton shares climbed 1.7% in premarket action after it beat estimates by 2 cents a share, with quarterly profit of 19 cents per share. Revenue was above estimates as well, with the oilfield services company saying its North American business continues to stage a healthy recovery.Baker Hughes (BKR) – The oilfield services company’s stock fell 1.4% in premarket action after it reported quarterly earnings of 12 cents per share, a penny a share above estimates. Revenue was essentially in line with expectations. Profit tumbled 40% from a year ago, impacted by severe winter weather.CSX (CSX) – CSX fell 2 cents a share short of estimates, with quarterly earnings of 93 cents per share. The rail operator’s revenue came in above forecasts. Pandemic-related disruptions and higher fuel costs ate into CSX’s bottom line. CSX slid 1% in premarket trading.Intuitive Surgical (ISRG) – Intuitive Surgical earned $3.52 per share for its latest quarter, well above the $2.63 a share consensus estimate. The surgical device maker’s revenue also beat forecasts, with procedures using the company’s devices increasing as the Covid-19 pandemic eases. The stock gained 3.9% in premarket trading.Tenet Healthcare (THC) – Tenet reported quarterly profit of $1.30 per share, compared to the 72 cents a share consensus estimate. The hospital operator’s revenue came in slightly above forecasts. Tenet said it was able to successfully deal with challenges related to both the pandemic and winter storms, and it also gave an upbeat outlook. Tenet added 2.7% in premarket trading.Interactive Brokers (IBKR) – Interactive Brokers came in 7 cents a share above estimates, with quarterly earnings of 98 cents per share. Revenue was well above estimates on a 53% jump in trading commissions. The stock added 2.1% in premarket trading.Edwards Lifesciences (EW) – Edwards shares gained 3.8% in the premarket after it beat estimates by 7 cents a share, with quarterly profit of 54 cents per share. Revenue was also above consensus forecasts and the medical device company also raised its full-year forecast on an anticipated increase in demand for heart-related procedures.","news_type":1},"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":602333381,"gmtCreate":1638969966940,"gmtModify":1638969966940,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Meme your mother&nbsp;","listText":"Meme your mother&nbsp;","text":"Meme your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602333381","repostId":"1160989369","repostType":2,"repost":{"id":"1160989369","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890853,"share":"https://www.laohu8.com/m/news/1160989369?lang=&edition=full","pubTime":"2021-12-07 23:27","market":"us","language":"en","title":"Meme stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1160989369","media":"Tiger Newspress","summary":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisit","content":"<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p>\n<p><img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 23:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC&nbsp;and&nbsp;GameStop&nbsp;climbed between 5% and 18%.</p>\n<p><img src=\"https://static.tigerbbs.com/c14f2bc9d526cf27d2ce20a66c8b481f\" tg-width=\"398\" tg-height=\"725\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d603202a0fc2cf4684ab0bc7c0441a79\" tg-width=\"403\" tg-height=\"428\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","ZOM":"Zomedica Pharmaceuticals Corp.","BBIG":"Vinco Ventures, Inc.","ATER":"Aterian Inc.","KOSS":"高斯电子","EXPR":"Express, Inc.","GME":"游戏驿站","MRIN":"Marin Software Inc.","NEGG":"Newegg Comm Inc.","CLOV":"Clover Health Corp","GREE":"Greenidge Generation Holdings Inc.","OCGN":"Ocugen","BB":"黑莓","PHUN":"Phunware, Inc.","BBBY":"3B家居"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160989369","content_text":"Meme stocks jumped in morning trading.Vinco Ventures,IronNet,Zomedica,Aterian,Digital World Acquisition,Greenidge Generation,Senseonics,Newegg,AMC and GameStop climbed between 5% and 18%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1009,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606614244,"gmtCreate":1638870615594,"gmtModify":1638870615594,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"I am betting on&nbsp;your mother","listText":"I am betting on&nbsp;your mother","text":"I am betting on your mother","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606614244","repostId":"1159607563","repostType":2,"repost":{"id":"1159607563","kind":"news","pubTimestamp":1638861435,"share":"https://www.laohu8.com/m/news/1159607563?lang=&edition=full","pubTime":"2021-12-07 15:17","market":"us","language":"en","title":"Ocugen Investors Are Betting On a Horse Than Can’t Win the Race","url":"https://stock-news.laohu8.com/highlight/detail?id=1159607563","media":"InvestorPlace","summary":"Don't go bottom-fishing with OCGN stock even if it's at an enticing support level","content":"<p>For technical traders, it might be tempting to accumulate shares of biopharmaceutical company&nbsp;<b>Ocugen</b>&nbsp;(NASDAQ:<b><u>OCGN</u></b>) because OCGN stock has come down to a seemingly fair price.</p>\n<p>Yet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.</p>\n<p>So, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.</p>\n<p>Moreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.</p>\n<p><b>A Closer Look at OCGN Stock</b></p>\n<p>Before talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.</p>\n<p>In February, May and November, the stock spiked to $15 before declining sharply.</p>\n<p>Therefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.</p>\n<p>On the other end of the spectrum, OCGN stock has strong support at $6.</p>\n<p>The stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.</p>\n<p>Checking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.</p>\n<p>Therefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.</p>\n<p>So, let’s see how Ocugen’s faring on the fiscal front.</p>\n<p><b>Financially Frail</b></p>\n<p>Just to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is&nbsp;known as Covaxin.</p>\n<p>Ocugen is&nbsp;co-developing&nbsp;Covaxin with India-based&nbsp;<b>Bharat Biotech</b>, and is advancing the drug in the U.S. and Canadian markets.</p>\n<p>It’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.</p>\n<p>Let’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.</p>\n<p>Right now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.</p>\n<p>During&nbsp;2021’s third quarter, Ocugen generated zero total revenues.</p>\n<p>The same could actually be said about the first three quarters of 2021.</p>\n<p>Now, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.</p>\n<p>That’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.</p>\n<p>So far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?</p>\n<p><b>Good News, Bad News</b></p>\n<p>Let’s start with a development that should provide some relief to OCGN stock holders.</p>\n<p><i>The Lancet</i>, a widely respected medical journal,published the results&nbsp;of a Phase 3 trial of Covaxin.</p>\n<p>The data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.</p>\n<p>That’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.</p>\n<p>Those lower figures might make Covaxin less useful in certain contexts.</p>\n<p>Worse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.</p>\n<p>That’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.</p>\n<p>The competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.</p>\n<p>Therefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Investors Are Betting On a Horse Than Can’t Win the Race</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Investors Are Betting On a Horse Than Can’t Win the Race\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the...</p>\n\n<a href=\"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/ocgn-stock-investors-are-betting-on-a-horse-than-cant-win-the-race/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159607563","content_text":"For technical traders, it might be tempting to accumulate shares of biopharmaceutical company Ocugen (NASDAQ:OCGN) because OCGN stock has come down to a seemingly fair price.\nYet, let’s not forget the old Warren Buffett saying. It goes something like this: price is what you pay, but value is what you actually get.\nSo, is OCGN a good value at its reduced price point? That depends, in large part, on Ocugen’s financials, which aren’t looking too healthy.\nMoreover, since Ocugen is a Covid-19 vaccine developer, we have to consider how the company is faring on the regulatory front. As it turns out, there are issues in that area, as well.\nA Closer Look at OCGN Stock\nBefore talking about support levels, we should discuss OCGN’s resistance level, which is definitely $15.\nIn February, May and November, the stock spiked to $15 before declining sharply.\nTherefore, if you’re bold enough to take a long position, you might consider taking profits at $15 just to stay safe.\nOn the other end of the spectrum, OCGN stock has strong support at $6.\nThe stock bounced off of that level in April and again in October, and stayed near $6 for five consecutive months starting in June.\nChecking in on Dec. 2, the share price is almost exactly $6. That might just be an eerie coincidence, but it feels meaningful.\nTherefore, from a price-action perspective, OCGN stock looks pretty tempting. Informed investors need to be big-picture thinkers, though, and check the company’s fundamentals as well.\nSo, let’s see how Ocugen’s faring on the fiscal front.\nFinancially Frail\nJust to give you a quick primer, Ocugen’s Covid-19 vaccine candidate is known as Covaxin.\nOcugen is co-developing Covaxin with India-based Bharat Biotech, and is advancing the drug in the U.S. and Canadian markets.\nIt’s worth noting that Ocugen also seeks to treat underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.\nLet’s be honest, though – Wall Street is much more interested in Covaxin’s progress (or lack thereof), which we’ll get to in a moment.\nRight now, the topic of discussion is Ocugen’s financials, and they’re not particularly encouraging.\nDuring 2021’s third quarter, Ocugen generated zero total revenues.\nThe same could actually be said about the first three quarters of 2021.\nNow, let’s look at the bottom-line results. During 2021’s first three quarters, Ocugen sustained a net earnings loss of $43,784,000.\nThat’s significantly worse than the $30,578,000 net loss from the comparable period of 2020.\nSo far, this analysis isn’t painting Ocugen in a positive light. Will the outlook brighten when we focus on Covaxin’s progress with regulators?\nGood News, Bad News\nLet’s start with a development that should provide some relief to OCGN stock holders.\nThe Lancet, a widely respected medical journal,published the results of a Phase 3 trial of Covaxin.\nThe data indicates that Covaxin demonstrated a 93.4% efficacy rate against severe Covid-19.\nThat’s a great result, but there are other numbers to consider. Specifically, Covaxin demonstrated 77.8% overall efficacy against Covid-19, 63.6% efficacy against asymptomatic Covid-19 and 65.2% efficacy against the delta variant strain.\nThose lower figures might make Covaxin less useful in certain contexts.\nWorse yet, the U.S. Food and Drug Administration (FDA) recently issued aclinical holdon an Investigational New Drug application (IND) to evaluate Covaxin outside of the U.S.\nThat’s a stumbling block on the regulatory pathway, which Ocugen definitely didn’t need right now.\nThe Bottom Line\nIt’s a shame that Ocugen couldn’t keep up in the race to develop a Covid-19 vaccine that would gain traction.\nThe competition is fierce in this area, and unfortunately, Ocugen isn’t in a strong financial position to outdo or outlast its peers.\nTherefore, even if it’s trading at a strong support level, OCGN stock simply isn’t a buy right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1029,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853539585,"gmtCreate":1634823296736,"gmtModify":1634823712607,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Mother fool","listText":"Mother fool","text":"Mother fool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853539585","repostId":"1171915283","repostType":2,"repost":{"id":"1171915283","kind":"news","pubTimestamp":1634817585,"share":"https://www.laohu8.com/m/news/1171915283?lang=&edition=full","pubTime":"2021-10-21 19:59","market":"us","language":"en","title":"7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen","url":"https://stock-news.laohu8.com/highlight/detail?id=1171915283","media":"Motley Fool","summary":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so f","content":"<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p>\n<p>Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p>\n<p>1. A path to EUA in the U.S.</p>\n<p>Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p>\n<p>The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p>\n<p>Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p>\n<p>Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p>\n<p>2. Supply deals already in hand</p>\n<p>Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p>\n<p>Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p>\n<p>3. Full rights to its COVID-19 vaccine</p>\n<p>Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p>\n<p>Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p>\n<p>4. A stronger pipeline</p>\n<p>Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p>\n<p>Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p>\n<p>5. More cash</p>\n<p>Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p>\n<p>As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p>\n<p>6. More potential near-term catalysts</p>\n<p>Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p>\n<p>What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p>\n<p>7. A more defensible valuation</p>\n<p>Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p>\n<p>Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171915283","content_text":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes that make Ocugen the smarter vaccine stock to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.\n1. A path to EUA in the U.S.\nOcugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.\nThe company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.\nMeanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.\nOcugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.\n2. Supply deals already in hand\nSome investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.\nOcugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,Takeda), and Gavi, the Vaccine Alliance.\n3. Full rights to its COVID-19 vaccine\nOcugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.\nNovavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.\n4. A stronger pipeline\nOther than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.\nNovavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.\n5. More cash\nCash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.\nAs of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.\n6. More potential near-term catalysts\nOcugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.\nWhat about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.\n7. A more defensible valuation\nOcugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.\nNovavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.","news_type":1},"isVote":1,"tweetType":1,"viewCount":851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":372941567,"gmtCreate":1619171841559,"gmtModify":1634288015707,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Retarded&nbsp;face","listText":"Retarded&nbsp;face","text":"Retarded face","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/372941567","repostId":"1144940040","repostType":4,"repost":{"id":"1144940040","kind":"news","pubTimestamp":1619165890,"share":"https://www.laohu8.com/m/news/1144940040?lang=&edition=full","pubTime":"2021-04-23 16:18","market":"sg","language":"en","title":"Singapore names new finance minister in cabinet reshuffle after setback in leadership succession","url":"https://stock-news.laohu8.com/highlight/detail?id=1144940040","media":"cnbc","summary":"KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new fi","content":"<div>\n<p>KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new finance minister.Wong is the current education minister and second finance minister, and has been ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore names new finance minister in cabinet reshuffle after setback in leadership succession</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore names new finance minister in cabinet reshuffle after setback in leadership succession\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 16:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new finance minister.Wong is the current education minister and second finance minister, and has been ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.cnbc.com/2021/04/23/singapore-cabinet-reshuffle-lawrence-wong-to-become-finance-minister.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1144940040","content_text":"KEY POINTSSingapore’s Prime Minister Lee Hsien Loong has named Lawrence Wong as the country’s new finance minister.Wong is the current education minister and second finance minister, and has been tipped as one of the potential successors to Lee.Wong will take over from Heng Swee Keat, who announced two weeks ago that he will step aside as Lee’s designated successor.SINGAPORE — Singapore’s Prime Minister Lee Hsien Loong has named a new finance minister, replacing Heng Swee Keat who announced two weeks ago that he willstep aside as Lee’s designated successor.Lawrence Wong, the country’s current education minister and second finance minister, will helm the finance portfolio from May 15,the prime minister’s office said on Friday.Wong is also the co-chair of Singapore’s taskforce on Covid-19, and has risen in prominence since the coronavirus outbreak last year.Wong is among potential candidatesthat analysts said could eventually take over from Lee as prime minister.The cabinet shuffle came after Heng's announcement threw Singapore's carefully planned leadership succession into disarray. Heng, who's 60 this year, had cited his age as an obstacle in steering the country in a post-pandemic world.Heng will relinquish his role as finance minister, but remains the country's deputy prime minister and coordinating minister for economic policies.In addition to Wong, analysts identified three other potential candidates for prime minister:Minister for Trade and Industry Chan Chun Sing, 51, who will become education minister in the new cabinet.Minister for Transport Ong Ye Kung, 51, who will become health minister.Desmond Lee, 44, who will remain as minister for national development.The ruling People’s Action Party has governed Singapore since the country’s independence in 1965. The party suffered one of itsworst electoral showingslast year, winning 83 out of 93 parliamentary seats and 61% of the votes.Lee, the current prime minister, had previously said he was ready to retireby the time he turns 70. However, he later indicated he would delay his handover to see Singapore through the Covid-19 crisis.Lee is 69 this year.After Heng’s surprise announcement, Lee said he would stay on as prime minister until a new successor emerges and is ready to take over.","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378192346,"gmtCreate":1619008614285,"gmtModify":1634289268600,"author":{"id":"3577579226988656","authorId":"3577579226988656","name":"Baaboon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577579226988656","authorIdStr":"3577579226988656"},"themes":[],"htmlText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","listText":"Please talk about Ocugen OCGN. They will be saving the world, together with India.&nbsp;","text":"Please talk about Ocugen OCGN. They will be saving the world, together with India.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/378192346","repostId":"1133987686","repostType":4,"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}